ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 083,71
-0,27%
Dow Jones
38 355,63
-0,38%
DAX
18 077,71
-0,36%
Brent Oil
87,425
-0,16%
Bitcoin
64 889,87
-2,29%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Actualités

AGEN Agenus Inc

7,18
0,72 (11,15%)
Dernière mise à jour : 17:01:31
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Agenus Inc AGEN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,72 11,15% 7,18 17:01:31
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,84 6,31 7,45 6,46
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202416:00BWBotensilimab/Balstilimab Data in MSS CRC Selected for the..
23/4/202413:30BWAgenus to Provide First Quarter 2024 Financial Report and..
12/4/202413:30BWAgenus Announces Updated Phase 1 Data and Progress on..
05/4/202422:30BWAgenus Announces Reverse Stock Split of Common Stock
14/3/202412:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/3/202413:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
05/3/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
29/2/202422:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202413:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
26/2/202422:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/2/202413:30BWAgenus to Participate in Leerink Partners Global Biopharma..
15/2/202414:02EDGAR2Form PRE 14A - Other preliminary proxy statements
15/2/202414:00EDGAR2Form 8-K - Current report
15/2/202413:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
14/2/202414:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202413:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
09/2/202423:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202414:00EDGAR2Form 8-K - Current report
31/1/202413:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
22/1/202415:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/1/202413:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
05/1/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/1/202413:30BWAgenus to Participate in B. Riley Healthcare Conference
04/1/202412:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202313:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
08/12/202322:15EDGAR2Form 8-K - Current report
17/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202312:30EDGAR2Form 8-K - Current report
07/11/202312:30BWAgenus Reports Third Quarter 2023 Results
26/10/202315:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
22/10/202318:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202310:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
16/10/202323:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202313:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
06/10/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202313:30BWAgenus To Host BOT/BAL Program Update at ESMO 2023
04/10/202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202322:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
31/8/202323:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202313:30BWAgenus to Participate in September Investor Conferences
23/8/202314:00EDGAR2Form 8-K - Current report
23/8/202314:00BWAgenus Prioritizes Resources to Accelerate Registration and..
09/8/202314:30BWSaponiQx Announces Breakthrough in Scaling Up of STIMULON™..

Dernières Valeurs Consultées

NASDAQ
AGEN
Agenus
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés